GlassScriptPhysician profile
Amanda M Day
NPI 1467099796
$4,894.64
in general payments reported to CMS, 2019-2025
28 companies · $1,272 in 2025
The $1,272 reported for 2025 was more than what 90% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $238 · 2022: $781 · 2023: $1,409 · 2024: $1,194 · 2025: $1,272.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,861 · Education: $13.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,861.49 |
| Education | $13.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $936.43 | 2021-2025 | Farxiga, Lokelma |
| Aurinia Pharma U.S., INC. | $617.94 | 2021-2025 | Lupkynis |
| Otsuka America Pharmaceutical, INC. | $452.60 | 2021-2025 | Jynarque |
| Mallinckrodt Hospital Products INC. | $398.59 | 2021-2023 | Acthar |
| Travere Therapeutics, INC. | $316.90 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $313.61 | 2023-2025 | |
| Vifor Pharma, INC. | $290.52 | 2022-2025 | Veltassa, Korsuva |
| Calliditas Therapeutics US INC. | $283.54 | 2022-2025 | Tarpeyo |
| Glaxosmithkline, LLC. | $175.69 | 2023-2025 | Benlysta, Shingrix, Arexvy |
| Amgen INC. | $169.85 | 2023-2025 | Tavneos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $160.83 | 2023-2025 | Jardiance |
| Kyowa Kirin, INC. | $108.05 | 2024-2025 | Crysvita |
| Horizon Therapeutics Plc | $91.94 | 2021-2022 | |
| Ardelyx, INC. | $89.34 | 2023-2025 | Ibsrela |
| Daiichi Sankyo INC. | $71.67 | 2021-2023 | Injectafer |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $62.78 | 2021-2023 | Soliris, Ultomiris |
| Xeris Pharmaceuticals, INC. | $46.91 | 2024 | Keveyis |
| Boston Scientific Corporation | $42.73 | 2024-2025 | General - Erectile Dysfunction, Wavewriter Alpha Prime 16 |
| Apellis Pharmaceuticals, INC. | $33.96 | 2025 | |
| Ani Pharmaceuticals, INC. | $33.16 | 2025 | Purified Cortrophin Gel |
| Opko Pharmaceuticals, LLC | $29.70 | 2021-2024 | Rayaldee |
| Abbvie INC. | $28.96 | 2025 | |
| Scpharmaceuticals INC. | $28.94 | 2025 | |
| Akebia Therapeutics INC | $27.24 | 2024 | Vafseo |
| Cormedix INC. | $25.00 | 2025 | Defencath |
| Janssen Pharmaceuticals, INC | $23.99 | 2024 | Xarelto |
| Urovant Sciences INC | $19.06 | 2022 | |
| Fresenius USA Marketing, INC. | $14.71 | 2024 | Velphoro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Day listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.